References
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30
- Goldman L, Schafer AI. Cecil medicine: expert consult premium edition. Philadelphia: Elsevier Health Sciences; 2011
- Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106–2131
- Mohler ML, Bohl CE, Jones A, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem 2009;52:3597–3617
- Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8:12–23
- Gunther JR, Parent AA, Katzenellenbogen JA. Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. ACS Chem Biol 2009;4:435–440
- Chenoweth DM, Harki DA, Phillips JW, et al. Cyclic pyrrole-imidazole polyamides targeted to the androgen response element. J Am Chem Soc 2009;131:7182–7188
- Nickols NG, Dervan PB. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci USA 2007;104:10418–10423
- Estebanez-Perpina E, Arnold LA, Nguyen P, et al. A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci USA 2007;104:16074–16079
- Jones JO, Bolton EC, Huang Y, et al. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci USA 2009;106:7233–7238
- Joseph JD, Wittmann BM, Dwyer MA, et al. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. Proc Natl Acad Sci USA 2009;106:12178–12183
- Norris JD, Joseph JD, Sherk AB, et al. Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands. Chem Biol 2009;16:452–460
- Moore TW, Mayne CG, Katzenellenbogen JA. Minireview: not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol 2009;24:683–695
- Smith DF, Toft DO. Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. Mol Endocrinol 2008;22:2229–2240
- Sivils JC, Storer CL, Galigniana MD, Cox MB. Regulation of steroid hormone receptor function by the 52-kDa FK506-binding protein (FKBP52). Curr Opin Pharmacol 2011;11:314–319
- Storer CL, Dickey CA, Galigniana MD, et al. FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol Metab 2011;22:481–490
- Riggs DL, Cox MB, Cheung-Flynn J, et al. Functional specificity of co-chaperone interactions with Hsp90 client proteins. Crit Rev Biochem Mol Biol 2004;39:279–295
- De Leon JT, Iwai A, Feau C, et al. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci USA 2011;108:11878–11883
- Liang S, Bian X, Sivils J, et al. Quantification of a new anti-cancer molecule MJC13 using a rapid, sensitive, and reliable liquid chromatography-tandem mass spectrometry method. Am J Modern Chromatogr 2014;1:1–11
- Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: a review. Anti-cancer drugs 2007;18:95–103
- French JT, Goins B, Saenz M, et al. Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide. J Vasc Intervent Radiol 2010;21:1271–1279
- Holback H, Yeo Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm Res 2011;28:1819–1830
- Xie H, Goins B, Bao A, et al. Effect of intratumoral administration on biodistribution of 64Cu-labeled nanoshells. Int J Nanomed 2012;7:2227–2238
- He S, Zhang C, Shafi AA, et al. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol 2013;42:35–43